Uterine Tissue Engineering Approaches: Current Strategies and Future Perspectives

Abstract

Uterine tissue engineering represents a rapidly evolving field aimed at addressing the complex challenge of uterine factor infertility and uterine tissue loss due to congenital anomalies, trauma, or oncological resections. This review synthesizes recent advances in scaffold materials, cellular therapies, and bioengineering techniques, emphasizing clinical translation, evidence-based outcomes, and future directions. The review targets clinicians and healthcare professionals seeking to understand the scientific basis, current clinical applications, and translational hurdles of uterine tissue engineering.

Introduction

The uterus plays a critical role in female reproductive health, providing a nurturing environment for embryo implantation and fetal development. Disorders such as congenital uterine anomalies, Asherman’s syndrome, and oncological resections can result in partial or complete loss of uterine function, significantly impacting fertility and quality of life. Conventional treatments, including uterine transplantation and surrogacy, are associated with ethical, immunological, and logistical challenges. Tissue engineering offers a promising alternative by aiming to regenerate functional uterine tissue using a combination of scaffolds, cells, and bioactive factors. This review discusses the scientific underpinnings, clinical relevance, and practical considerations in the development and application of uterine tissue engineering approaches.

Epidemiology / Disease Burden

Uterine factor infertility affects approximately 3-5% of women worldwide, with higher prevalence in populations with increased rates of congenital anomalies, intrauterine adhesions, or post-surgical tissue loss. The burden extends beyond infertility, encompassing recurrent pregnancy loss, menstrual abnormalities, and significant psychosocial distress. Epidemiological studies indicate that the incidence of uterine damage is rising, particularly due to increased gynecological surgeries and improved cancer survival rates necessitating uterine resection. The unmet need for effective uterine reconstruction has catalyzed research into regenerative solutions.

Pathophysiology

The unique structure of the uterus, comprising the endometrium, myometrium, and perimetrium, presents significant challenges for tissue regeneration. The endometrium undergoes cyclical regeneration, while the myometrium provides contractile function; both layers require precise cellular and extracellular matrix (ECM) organization for optimal functionality. Pathological tissue loss disrupts the native architecture, impairs vascularization, and compromises the hormonal responsiveness necessary for implantation and gestation. Fibrosis, chronic inflammation, and impaired stem cell niches further complicate healing, necessitating targeted interventions that restore both structure and function.

Risk Factors

Risk factors for uterine tissue loss include congenital conditions such as Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, iatrogenic injury following curettage, myomectomy, or hysterectomy, infectious etiologies like tuberculosis, and malignancies requiring partial or total uterine resection. Additional risk factors encompass intrauterine device complications, severe endometrial infections, and radiation-induced uterine damage. Understanding these risk factors is essential for identifying suitable candidates for tissue engineering interventions and for tailoring reconstructive strategies.

Clinical Features

Patients with uterine tissue defects may present with primary or secondary infertility, recurrent implantation failure, amenorrhea or hypomenorrhea, pelvic pain, and obstetric complications. Clinical evaluation often reveals an absent or hypoplastic uterus on imaging, intrauterine adhesions, or defective endometrial lining. The spectrum of clinical features depends on the extent and location of tissue loss, underlying etiology, and associated comorbidities. Early recognition and diagnosis are crucial for optimal management and for timely consideration of regenerative therapies.

Diagnosis

Diagnosis of uterine tissue defects relies on a combination of clinical history, pelvic examination, imaging modalities (ultrasound, MRI), and hysteroscopic assessment. Sonohysterography and three-dimensional ultrasound provide detailed visualization of uterine anatomy, while MRI offers superior soft tissue contrast for evaluating myometrial integrity. Hysteroscopy remains the gold standard for direct visualization and biopsy of the endometrial cavity. Recent advances in molecular diagnostics, including gene expression profiling and endometrial receptivity assays, contribute to the comprehensive assessment of uterine function and regenerative potential.

Treatment & Management

Conventional management options for uterine tissue loss include surgical adhesiolysis, endometrial ablation, and, in select cases, uterine transplantation. Conservative therapies often yield suboptimal results in extensive tissue loss. Uterine transplantation, though promising, is limited by donor availability, surgical complexity, need for immunosuppression, and ethical considerations. Tissue engineering approaches aim to overcome these limitations by utilizing autologous or allogeneic stem cells seeded onto biocompatible scaffolds to reconstruct functional uterine tissue. Clinical management requires a multidisciplinary approach, incorporating reproductive endocrinologists, surgeons, and regenerative medicine specialists.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in uterine tissue engineering. Decellularized uterine scaffolds derived from animal or human tissue retain native ECM architecture and have shown promise in preclinical models. Synthetic and natural biomaterials, including collagen, gelatin, and polycaprolactone, are being explored for their mechanical and biocompatible properties. Stem cell-based strategies—using mesenchymal stem cells, endometrial stem/progenitor cells, and induced pluripotent stem cells—have demonstrated potential in promoting endometrial regeneration, angiogenesis, and immunomodulation. Bioprinting technologies enable the fabrication of complex, patient-specific uterine constructs. Preclinical studies in rodents, rabbits, and primates have shown successful implantation, vascularization, and, in some cases, live births. However, translation to human clinical application remains in early investigational stages.

Guideline Recommendations

Currently, there are no established clinical guidelines for uterine tissue engineering in humans due to the experimental nature of these therapies. However, consensus recommendations emphasize the need for rigorous preclinical validation, standardized protocols for scaffold fabrication and cell sourcing, and long-term safety and efficacy assessments. Ethical considerations, including informed consent, donor-recipient matching, and risk-benefit analysis, are paramount. Professional societies advocate for multidisciplinary collaboration, robust clinical trial design, and transparent reporting of outcomes to guide future recommendations as the field matures.

Conclusion

Uterine tissue engineering holds transformative potential for addressing uterine factor infertility and for restoring uterine function following tissue loss. Advances in biomaterials, stem cell biology, and biofabrication have brought the prospect of functional uterine regeneration closer to clinical reality. Despite promising preclinical evidence, significant translational challenges remain, including scaffold integration, vascularization, immunogenicity, and regulatory hurdles. Continued multidisciplinary research, ethical vigilance, and well-designed clinical trials are essential for safe and effective clinical translation. For clinicians, staying informed about emerging technologies and participating in collaborative research networks will be key to integrating these innovations into future reproductive healthcare.